Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:20 PM
Ignite Modification Date:
2025-12-24 @ 5:20 PM
NCT ID:
NCT00856050
Brief Summary:
The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR).
Detailed Description:
* Participants will take letrozole orally once a day. During the research study the following tests and procedures will be performed:
* Visit 1 (Day 1): physical examination, vital signs and blood work
* Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan
* Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan
* Participants will remain on the study drug as long as they do not have any serious sife effect and their disease does not get worse
Study:
NCT00856050
Study Brief:
Protocol Section:
NCT00856050